Abstract:
Mineral and bone metabolism disorders remain a major concern for nephrologists, due to
their clinical complications and impact on vital prognosis. The aim of this study is to analyze
the clinical, biological, therapeutic and evolutionary aspects of mineral and bone disorders in
chronic hemodialysis patients, and to estimate the percentage of patients who meet the
targets required by the international KDIGO (Kidney Disease Improval Global
recommendations).
We conducted a single-center cross-sectional study over 6 months (November 2022 to April
2023) of 73 chronic hemodialysis patients.
Demographic, clinical, biological and radiological parameters were determined, 36 women
and 37 men with a mean age of 44 years were enrolled. Initial nephropathy was of
undetermined origin in 67% of cases. Clinically, 61.67% of our patients complained of bone
pain, 53.42% had arthralgia predominantly in the knees, 12.32% had walking difficulty,
muscular fatigue in 19.17% of cases, and pruritus in 31.5%. Biologically, hypocalcemia was
detected in 20.5%, while mean hyperphosphatemia was found in 53.42% .
Among our patients, 63% had hyperparathyroidism, and only 27.4% had PTH levels within
the KDIGO guidelines.
Standard radiographs revealed signs of secondary hyperparathyroidism consistent with the
biological data .
This study highlights the high prevalence of mineral and bone disorders in chronic
hamodialysis patients, why the importance of prevention, starting with early management of
chronic kidney disease and effective dialysis.
